for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Caladrius Biosciences Inc

CLBS.OQ

Latest Trade

2.27USD

Change

-0.09(-3.81%)

Volume

6,010

Today's Range

2.27

 - 

2.38

52 Week Range

2.03

 - 

5.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.36
Open
2.34
Volume
6,010
3M AVG Volume
0.44
Today's High
2.38
Today's Low
2.27
52 Week High
5.40
52 Week Low
2.03
Shares Out (MIL)
10.40
Market Cap (MIL)
24.13
Forward P/E
-1.25
Dividend (Yield %)
--

Next Event

Caladrius Biosciences Inc at Dawson James Securities Small Cap Growth Conference

Latest Developments

More

Caladrius Biosciences Reports Q2 Loss Per Share $0.49

Caladrius Biosciences Reports Q3 Loss Per Share Of $0.36 From Continuing Operations

Caladrius Biosciences Q2 Loss Per Share $0.42 From Continuing Operations

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Caladrius Biosciences Inc

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.

Industry

Biotechnology & Drugs

Contact Info

110 Allen Rd

+1.908.8420100

https://www.caladrius.com/

Executive Leadership

David J. Mazzo

President, Chief Executive Officer, Director

Joseph Talamo

Chief Financial Officer, Senior Vice President

Douglas W. Losordo

Chief Medical Officer

Gregory B. Brown

Director

Cynthia L. Schwalm

Director

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-4.990

2017

-1.780

2018

-1.670

2019(E)

-1.857
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
0.81
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-42.89
Return on Equity (TTM)
-37.56

Latest News

Latest News

BRIEF-Roche Says Phase III Study On Alecensa Meets Primary Endpoint

* SAYS WILL TO ANNOUNCE RESULTS FROM THE PHASE III ALESIA STUDY, SHOWING THAT ALECENSA® (ALECTINIB) MET ITS PRIMARY ENDPOINT OF INVESTIGATOR-ASSESSED (INV) PROGRESSION-FREE SURVIVAL (PFS)

BRIEF-Caladrius Biosciences Receives Sakigake Expedited Review Designation In Japan For CLBS12 For Treating Critical Limb Ischemia

* CALADRIUS BIOSCIENCES RECEIVES SAKIGAKE EXPEDITED REVIEW DESIGNATION IN JAPAN FOR CLBS12 FOR TREATING CRITICAL LIMB ISCHEMIA Source text for Eikon: Further company coverage:

BRIEF-Caladrius Biosciences Q4 Loss Per Share $0.40 From Cont Ops

* CALADRIUS BIOSCIENCES REPORTS 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS

BRIEF-Caladrius Biosciences Doses First Patient In Mid-Stage Critical Limb Ischemia Trial In Japan

* CALADRIUS BIOSCIENCES DOSES FIRST PATIENT WITH CLBS12 IN PHASE 2 CRITICAL LIMB ISCHEMIA TRIAL IN JAPAN Source text for Eikon: Further company coverage:

BRIEF-Caladrius Biosciences Acquires Exclusive Worldwide Rights To Data Set, Regulatory Filings For CD34+ Cell Therapy Program

* CALADRIUS BIOSCIENCES ACQUIRES AN EXCLUSIVE LICENSE TO A LATE STAGE CD34+ CELL THERAPY PROGRAM FOR THE TREATMENT OF REFRACTORY ANGINA

BRIEF-Caladrius Biosciences Entered Common Stock Sales Agreement With H.C. Wainwright & Co

* CALADRIUS BIOSCIENCES INC - ENTERED INTO A COMMON STOCK SALES AGREEMENT WITH H.C. WAINWRIGHT & CO HAVING AGGREGATE OFFERING PRICE OF UP TO $12 MILLION Source text: (http://bit.ly/2ER7sY9) Further company coverage:

BRIEF-Caladrius Biosciences reports 2017 third quarter results

* Q3 loss per share $0.38 from continuing operations Source text for Eikon: Further company coverage:

BRIEF-Caladrius Biosciences files for resale of co's common stock by the selling stockholders

* Files for resale of up to 932,204 shares of Co's common stock by the selling stockholders - SEC filing Source text for Eikon: Further company coverage:

BRIEF-Caladrius Biosciences Q2 loss per share $0.22 from continuing operations

* Q2 loss per share $0.22 from continuing operations Source text for Eikon: Further company coverage:

BRIEF-Caladrius Biosciences Q1 loss per share $1.12

* Caladrius Biosciences announces 2017 first quarter financial results

BRIEF-Caladrius Biosciences Q4 reports loss per share of $0.73

* Caladrius Biosciences announces 2016 fourth quarter and full year financial results

Roche to start new trial of AC Immune drug against Alzheimer's

Roche is starting a second late-stage trial of investigational Alzheimer's drug crenezumab that it is developing with Swiss biotech AC Immune, shrugging off failures of similar drugs against the memory-robbing disease.

BRIEF-Caladrius Biosciences awarded $12.2 mln grant from CIRM supporting Phase 2 trial of CLBS03

* Caladrius Biosciences awarded $12.2 million grant from CIRM in support of Phase 2 clinical trial of CLBS03 to treat type 1 diabetes

BRIEF-Caladrius Biosciences announces addition of three clinical sites

* Caladrius Biosciences announces addition of three clinical sites, including university of California, San Francisco, for the ongoing Phase 2 study of CLBS03 in T1D

BRIEF-Caladrius Biosciences updates status of receipt of funds for portion of previously announced private placement

* Caladrius biosciences updates status of receipt of funds for a portion of previously announced private placement

BRIEF-Caladrius Biosciences Q3 revenue $9.3 mln

* Caladrius Biosciences Inc - affirms 2016 revenue guidance to exceed $30 million or a greater than 30% increase compared with 2015

BRIEF-Caladrius biosciences begins second cohort of mid-stage trial for treating diabetes

* Caladrius Biosciences has modified T-rex study protocol to allow for an earlier than planned resumption of enrollment for remaining patients based on DSMB recommendation

BRIEF-Caladrius Biosciences increases size of board from eight to nine

* Says increased size of board from eight to nine Source text (http://bit.ly/2dvHye1) Further company coverage:

BRIEF-Caladrius biosciences appoints Gregory R. Brown, MD, to its board of directors

* Caladrius biosciences appoints Gregory R. Brown, MD, to its board of directors Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up